

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Morrison Susan</u> (Last) (First) (Middle) <u>C/O TANDEM DIABETES CARE, INC.,</u> <u>11045 ROSELLE STREET</u> (Street) <u>SAN DIEGO CA 92121</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>11/13/2013</u>	3. Issuer Name and Ticker or Trading Symbol <u>TANDEM DIABETES CARE INC [TNDM]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>CAO</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series B Preferred Stock	(1)	(2)	Common Stock	1,333	0.00	D	
Series C Preferred Stock	(1)	(2)	Common Stock	738	0.00	D	
Series D Preferred Stock	(1)	(2)	Common Stock	2,806	0.00	D	
Preferred Stock Warrant	(3)	08/31/2021	Series D Preferred Stock ⁽⁴⁾	612 ⁽⁴⁾	4.4 ⁽⁴⁾	D	
Preferred Stock Warrant	(3)	05/25/2022	Series D Preferred Stock ⁽⁵⁾	318 ⁽⁵⁾	4.4 ⁽⁵⁾	D	
Preferred Stock Warrant	(3)	08/21/2022	Series D Preferred Stock ⁽⁶⁾	439 ⁽⁶⁾	4.4 ⁽⁶⁾	D	
Incentive Stock Option ⁽⁷⁾	(8)	(9)	Common Stock	447	11.73	D	
Incentive Stock Option ⁽⁷⁾	(10)	(9)	Common Stock	746	11.73	D	
Incentive Stock Option ⁽⁷⁾	(11)	(9)	Common Stock	2,685	10.72	D	
Incentive Stock Option ⁽⁷⁾	(12)	(9)	Common Stock	149	10.72	D	
Incentive Stock Option ⁽⁷⁾	(13)	(9)	Common Stock	358	25.13	D	
Incentive Stock Option ⁽⁷⁾	(14)	(9)	Common Stock	95,488	1.11	D	

Explanation of Responses:

- The securities are immediately convertible.
- The expiration date is not relevant to the conversion of these securities.
- The warrants are immediately exercisable.
- Upon the consummation of the Issuer's initial public offering, these warrants will automatically become exercisable for 365 shares of the Issuer's common stock at an exercise price of \$7.37 per share.
- Upon the consummation of the Issuer's initial public offering, these warrants will automatically become exercisable for 189 shares of the Issuer's common stock at an exercise price of \$7.37 per share.
- Upon the consummation of the Issuer's initial public offering, these warrants will automatically become exercisable for 261 shares of the Issuer's common stock at an exercise price of \$7.37 per share.
- Granted pursuant to the Issuer's Tandem Diabetes Care, Inc. 2006 Stock Incentive Plan.
- The date of grant of the option was 12/13/2007. All shares subject to the option vested as to 25% on 12/13/2008 and in 36 equal monthly installments thereafter.
- The expiration date for these options is 10 years from the date of grant.
- The date of grant of the option was 9/10/2008. All shares subject to the option vested as to 25% on 9/10/2009 and in 36 equal monthly installments thereafter.
- The date of grant of the option was 8/20/2009. All shares subject to the option vested as to 25% on 8/20/2010 and in 36 equal monthly installments thereafter.
- The date of grant of the option was 1/22/2010. All shares subject to the option vested as to 25% on 1/22/2011 and continue to vest in 36 equal monthly installments thereafter.
- The date of grant of the option was 3/1/2012. All shares subject to the option vested as to 25% on 3/1/2013 and continue to vest in 36 equal monthly installments thereafter.
- The date of grant of the option was 4/23/2013. All shares subject to the option will vest in 24 equal monthly installments commencing on 4/23/2013.

Remarks:

/s/ David B. Berger, Attorney-in-Fact for Susan M. Morrison 11/13/2013

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

The undersigned hereby constitutes and appoints David B. Berger, John Cajigas, Leigh Vosseller and Bruce Feuchter, or any of them signing individually, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer of Tandem Diabetes Care, Inc. (the "Company"), Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules and regulations thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Forms 3, 4s and 5s and timely file such form with the SEC and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform each and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution and revocation, hereby ratifying and confirming all that each such attorney-in-fact, or each such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that each of the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

The undersigned agrees that each such attorney-in-fact may rely entirely on information furnished orally or in writing by the undersigned to each such attorney-in-fact. The undersigned also agrees to indemnify and hold harmless the Company and each such attorney-in-fact against any losses, claims, damages or liabilities (or actions in these respects) that arise out of or are based on any untrue statement or omission of necessary facts in the information provided by the undersigned to such attorney-in-fact for purposes of executing, acknowledging, delivering and filing Forms 3, 4s or 5s (including amendments thereto) and agrees to reimburse the Company and each such attorney-in-fact for any legal or other expenses reasonably incurred in connection with investigating or defending against any such loss, claim, damage, liability or action.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4s and 5s with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 6th day of November 2013.

/s/ Susan M. Morrison